共 6 条
[2]
Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial[J] . Diane M Harper,Eduardo L Franco,Cosette M Wheeler,Anna-Barbara Moscicki,Barbara Romanowski,Cecilia M Roteli-Martins,David Jenkins,Anne Schuind,Sue Ann Costa Clemens,Gary Dubin.The Lancet . 2006 (9518)
[3]
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial[J] . Luisa L Villa,Ronaldo LR Costa,Carlos A Petta,Rosires P Andrade,Kevin A Ault,Anna R Giuliano,Cosette M Wheeler,Laura A Koutsky,Christian Malm,Matti Lehtinen,Finn Egil Skjeldestad,Sven-Eric Olsson,Margareta Steinwall,Darron R Brown,Robert J Kurman,Brigitte M Ronnett,Mark H Stoler,Alex Ferenczy,
[5]
HPV16L1capsidprotein expressed from viable adenovirus recombinants elicits neutralizing antibody inmice .2 Berg M,Gambhira R,Siracusa M,Hoiczyk E,Roden R,Ketner G. Vaccine . 2007
[6]
Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins .2 Hagensee ME,Yaegashi N,Galloway DA. Journal of Virology . 1993